Literature DB >> 6339569

Lichen planus pemphigoides: clinical and immunofluorescent findings in four cases.

R G Mora, L T Nesbitt, J B Brantley.   

Abstract

During the last 5 years we examined four black male patients who had features of both lichen planus (LP) and bullous pemphigoid (BP). The clinical disorder included classical lesions of LP along with bullae that developed subsequently and arose on both lesional and nonlesional skin. Histologic findings correlated well with the type of lesion on which biopsy was done, as did the immunofluorescent findings. All patients had features of both LP and BP by direct immunofluorescence and of BP by indirect immunofluorescence of serum and blister fluid.

Entities:  

Mesh:

Year:  1983        PMID: 6339569     DOI: 10.1016/s0190-9622(83)70035-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Ultrastructural localization of the binding sites of antibasement membrane zone antibodies in lichen planus pemphigoides on 1.0 M sodium chloride-separated skin.

Authors:  S Ikeda; Y Song; H Yaguchi; K Naito; S Morioka; H Ogawa; T Muramatsu
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

3.  Childhood lichen planus pemphigoides triggered by chickenpox.

Authors:  T S Mohanarao; Gummalla Ajay Kumar; Kavya Chennamsetty; T Priyadarshini
Journal:  Indian Dermatol Online J       Date:  2014-12

4.  Histologic characterization of cellular infiltration in autoimmune subepidermal bullous diseases in a tertiary hospital in Saudi Arabia.

Authors:  Hessah F BinJadeed; Alanoud M Alyousef; Fahad M Alsaif; Ahmed A Alhumidi; Homaid O Alotaibi
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-04-24

Review 5.  Molecular diagnosis in autoimmune skin blistering conditions.

Authors:  J V Otten; T Hashimoto; M Hertl; A S Payne; C Sitaru
Journal:  Curr Mol Med       Date:  2014-01       Impact factor: 2.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.